Welcome, Safe Harbor, Agenda
John Borgeson
Key Messages, What to Expect Today
Victor Perlroth, MD
Tarcocimab and KSI-501: Retinal Vascular Diseases
Charles Wykoff, MD, PhD
KSI-101: Macular Edema Secondary to Inflammation (MESI)
Sumit Sharma, MD
What is MESI?
What causes MESI?
What is the unmet need?
How can this unmet need be addressed?
Phase 1b APEX Study — Diabetic Macular Edema and MESI cohorts
How do the APEX data compare?
Charles Wykoff, MD, PhD
PEAK and PINNACLE: KSI-101 pivotal program
Dolly S. Chang, MD, MPH, PhD
A patient's MESI journey
Victor Perlroth, MD
Commercial opportunity
Summary, Q&A, Closing
Kodiak Management Team and Industry Leaders